St-Jean E, Blain F, Comtois R
Department of Medicine, University of Montreal, Quebec, Canada.
Clin Endocrinol (Oxf). 1996 Mar;44(3):305-9. doi: 10.1046/j.1365-2265.1996.663486.x.
Large amounts of antigen may produce falsely low values in immunoradiometric assays due to the so-called high dose, hook effect. The study was designed to identify the clinical and biochemical features of patients with pituitary macroadenomas in whom a high dose PRL hook effect was documented.
The clinical and biochemical features of four patients with the high dose PRL hook effect were compared with those of 54 patients with pituitary non-functioning adenomas and 11 with macroprolactinomas who underwent transsphenoidal microsurgery between 1989 and 1994.
The presence of the high dose PRL hook effect was confirmed by an increase in the initial PRL concentration when the immunoradiometric assay was processed after dilutions of the serum. This phenomenon was observed in 5.8% (4/69) of patients with pituitary macroadenomas. Undiluted median (range) PRL levels were 9140 (1530-83850), 1530 (162-3210) and 2110 mU/l (1470-45,000) in patients with macroprolactinoma, non-functioning macroadenoma and the hook effect, respectively. In patients with the hook effect, the median PRL levels increased to 384,720 (317,520-950,000) mU/l when the assay was performed after serum dilution. The proportion of males was 9.9% (1/11) in the macroprolactinoma group, 46.3% (25/54) in the non-functioning macroadenoma group and 100% (4/4) in patients with the hook effect. Patients with prolactinoma and non-functioning adenoma had mean tumour sizes of 20 +/- 9 and 27 +/- 11 mm (SD), respectively, while in the hook effect group it was 51 +/- 10 mm.
This study suggests that the high dose PRL hook effect is observed particularly in patients with very large tumours. The immunoradiometric PRL assay must be performed with serum dilution in order to overcome the high dose PRL hook effect in all new patients with pituitary macroadenomas who may have a prolactinoma.
在免疫放射分析中,大量抗原可能因所谓的高剂量钩状效应而产生假性低值。本研究旨在确定记录到高剂量催乳素(PRL)钩状效应的垂体大腺瘤患者的临床和生化特征。
将4例出现高剂量PRL钩状效应患者的临床和生化特征,与1989年至1994年间接受经蝶窦显微手术的54例垂体无功能腺瘤患者和11例大泌乳素瘤患者的特征进行比较。
当血清稀释后进行免疫放射分析时,初始PRL浓度升高证实了高剂量PRL钩状效应的存在。在5.8%(4/69)的垂体大腺瘤患者中观察到这种现象。大泌乳素瘤、无功能大腺瘤和钩状效应患者未稀释的PRL水平中位数(范围)分别为9140(1530 - 83850)、1530(162 - 3210)和2110 mU/l(1470 - 45000)。在出现钩状效应的患者中,血清稀释后进行检测时,PRL水平中位数增至384720(317520 - 950000)mU/l。大泌乳素瘤组男性比例为9.9%(1/11),无功能大腺瘤组为46.3%(25/54),钩状效应患者组为100%(4/4)。泌乳素瘤和无功能腺瘤患者的平均肿瘤大小分别为20±9和27±11 mm(标准差),而钩状效应组为51±10 mm。
本研究表明,高剂量PRL钩状效应尤其在肿瘤非常大的患者中观察到。对于所有可能患有泌乳素瘤的垂体大腺瘤新患者,必须进行血清稀释的免疫放射PRL检测,以克服高剂量PRL钩状效应。